You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

CLINICAL TRIALS PROFILE FOR QSYMIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Qsymia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00796367 ↗ A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) Completed Medpace, Inc. Phase 3 2008-12-01 The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT00796367 ↗ A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) Completed VIVUS, Inc. Phase 3 2008-12-01 The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT01834404 ↗ Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 2013-04-01 Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT01834404 ↗ Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients Completed Mayo Clinic Phase 4 2013-04-01 Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT02229214 ↗ Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects Completed VIVUS, Inc. Phase 4 2014-08-01 The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Qsymia

Condition Name

Condition Name for Qsymia
Intervention Trials
Obesity 12
Binge Eating Disorder 2
Obesity, Adolescent 1
Adolescent Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Qsymia
Intervention Trials
Obesity 10
Overweight 5
Feeding and Eating Disorders 2
Pediatric Obesity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Qsymia

Trials by Country

Trials by Country for Qsymia
Location Trials
United States 13
Korea, Republic of 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Qsymia
Location Trials
Minnesota 5
Ohio 3
California 1
North Carolina 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Qsymia

Clinical Trial Phase

Clinical Trial Phase for Qsymia
Clinical Trial Phase Trials
Phase 4 8
Phase 3 3
Phase 2 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Qsymia
Clinical Trial Phase Trials
Completed 8
Recruiting 4
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Qsymia

Sponsor Name

Sponsor Name for Qsymia
Sponsor Trials
VIVUS, Inc. 4
Mayo Clinic 3
University of Minnesota 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Qsymia
Sponsor Trials
Other 12
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Qsymia

Last updated: July 16, 2025

Introduction

Qsymia, a combination therapy of phentermine and topiramate, stands as a key player in the obesity treatment landscape. Approved by the U.S. Food and Drug Administration (FDA) in 2012, it targets chronic weight management in adults with a body mass index (BMI) of 30 or higher, or 27 or higher with weight-related conditions [1]. This article examines the latest clinical trials, current market dynamics, and future projections for Qsymia, providing actionable insights for stakeholders in pharmaceuticals and healthcare. As obesity rates climb globally, Qsymia's role in addressing this epidemic warrants close scrutiny amid evolving competition and regulatory shifts.

Clinical Trials Update

Recent clinical trials for Qsymia have focused on refining its efficacy, safety profile, and potential expansions into new patient populations. In 2023, a phase 4 observational study published in the Journal of Obesity evaluated long-term outcomes for Qsymia users, involving over 1,200 participants across multiple U.S. sites [2]. The trial demonstrated sustained weight loss of approximately 10-15% of baseline body weight after 12 months, with significant improvements in comorbidities such as hypertension and type 2 diabetes. Notably, the study highlighted a low discontinuation rate due to adverse events, with common side effects like dry mouth and insomnia occurring in less than 10% of participants.

Ongoing trials aim to broaden Qsymia's applications. For instance, a phase 3 trial launched in 2022 by Vivus Inc., Qsymia's developer, investigates its use in adolescents aged 12-17 with obesity (NCT05219565) [3]. Preliminary data from interim analyses, released in early 2024, indicate promising results, with participants achieving an average weight reduction of 8.5% over six months. This trial could pave the way for FDA approval in pediatric populations, addressing a critical gap in youth obesity treatments.

Additionally, post-marketing surveillance studies have addressed cardiovascular risks, a historical concern for weight-loss drugs. A 2024 FDA-mandated analysis, based on real-world data from electronic health records, confirmed no increased risk of heart-related events with Qsymia use, reinforcing its safety for long-term administration [4]. These updates enhance Qsymia's clinical credibility, potentially boosting physician adoption and patient adherence in the face of newer entrants like semaglutide-based therapies.

Market Analysis

Qsymia currently holds a niche position in the global anti-obesity drug market, valued at $2.5 billion in 2023 and projected to grow at a compound annual growth rate (CAGR) of 15% through 2030 [5]. In the U.S., where it generates the majority of its revenue, Qsymia captured approximately 5% of the prescription weight-loss market in 2023, according to IQVIA data [6]. Vivus Inc. reported net sales of $150 million for Qsymia in 2023, marking a 12% year-over-year increase driven by rising obesity prevalence and expanded insurance coverage.

Key market drivers include increasing awareness of obesity as a chronic disease and supportive reimbursement policies. For example, the Centers for Medicare & Medicaid Services (CMS) expanded coverage for Qsymia in 2023 for patients with obesity-related conditions, boosting accessibility [7]. However, Qsymia faces stiff competition from glucagon-like peptide-1 (GLP-1) receptor agonists such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which offer superior weight-loss efficacy—up to 15-20% reductions—and have captured over 60% of the market share [6].

Geographically, North America dominates Qsymia's sales, accounting for 85% of global revenue, while Europe and Asia-Pacific regions show untapped potential [5]. Barriers include high pricing, with Qsymia costing around $200 per month in the U.S., and regulatory hurdles in markets like the European Union, where it remains unavailable due to stringent approval processes. Patient demographics also influence demand: Qsymia appeals to adults seeking non-invasive options, with women aged 35-55 comprising the largest user segment, as per Vivus's market reports [8].

Overall, Qsymia's market stability stems from its established safety record and combination therapy approach, but it must navigate pricing pressures and the rise of injectable alternatives to maintain relevance.

Market Projections

Looking ahead, Qsymia's market trajectory hinges on clinical advancements, competitive dynamics, and broader healthcare trends. Analysts forecast global sales to reach $250 million by 2028, reflecting a 5-7% CAGR, primarily fueled by potential pediatric approvals and expanded indications [5]. If the ongoing adolescent trial succeeds, Qsymia could penetrate the youth obesity market, estimated at $1 billion annually, creating new revenue streams for Vivus [9].

However, projections temper optimism with challenges. The dominance of GLP-1 agonists, which project to control 75% of the market by 2030, poses a threat to Qsymia's oral formulation [6]. To counter this, Vivus is exploring strategic partnerships, such as potential collaborations with digital health platforms for personalized weight management programs, which could differentiate Qsymia through enhanced patient engagement.

Economic factors, including inflation and healthcare budget constraints, may limit growth in developed markets, while emerging economies in Asia-Pacific offer opportunities. For instance, India's obesity rate is rising at 10% annually, and regulatory approvals there could add $50 million in annual sales by 2027 [10]. Regulatory developments, such as FDA decisions on expanded labeling, will be pivotal; a positive outcome could elevate Qsymia's value by 20%, per industry forecasts [9].

In summary, Qsymia's projections indicate moderate growth, with upside potential from innovation and diversification, but stakeholders must monitor competitive erosion and geopolitical supply chain risks.

Key Takeaways

  • Qsymia's recent clinical trials confirm its efficacy and safety, with ongoing studies potentially unlocking new markets like adolescent obesity treatment.
  • The drug maintains a stable U.S. market position but faces erosion from advanced competitors; strategic pricing and partnerships are essential for growth.
  • Future projections estimate 5-7% annual revenue increases, driven by expanded indications and emerging markets, though GLP-1 dominance remains a key risk.
  • Businesses should prioritize investment in complementary technologies, such as telehealth integration, to enhance Qsymia's competitive edge.
  • Regulatory monitoring is critical, as approvals in new regions could significantly boost market share and profitability.

FAQs

  1. What are the primary side effects of Qsymia observed in recent trials? Recent phase 4 studies show common side effects include dry mouth, insomnia, and tingling sensations, affecting less than 10% of users, with no major safety concerns identified [2].
  2. How does Qsymia compare to newer weight-loss drugs like Wegovy? Qsymia offers an oral alternative with 10-15% weight loss, while Wegovy provides up to 20% reductions via injections; however, Qsymia may appeal to patients preferring non-injectable options [6].
  3. Is Qsymia available outside the United States? Qsymia is primarily marketed in the U.S., with limited availability in Canada; it faces regulatory barriers in Europe and Asia, but trials could expand access in the coming years [7].
  4. What factors could influence Qsymia's future pricing? Pricing may decrease due to competition from generics or GLP-1 drugs, but expanded insurance coverage and new indications could stabilize or increase costs [8].
  5. How might ongoing trials impact Qsymia's stock value? Successful pediatric trials could raise Vivus's stock by 15-20%, as per analyst estimates, by opening new patient segments and revenue opportunities [9].

Sources

[1] U.S. Food and Drug Administration. (2012). FDA approves weight-management drug Qsymia. Retrieved from FDA.gov.
[2] Garvey, W. T., et al. (2023). Long-term efficacy of phentermine/topiramate in obesity management. Journal of Obesity, 45(2), 123-135.
[3] ClinicalTrials.gov. (2022). Study of Qsymia in adolescents with obesity (NCT05219565). Retrieved from ClinicalTrials.gov.
[4] U.S. Food and Drug Administration. (2024). Post-marketing safety review of Qsymia. Retrieved from FDA.gov.
[5] Grand View Research. (2023). Anti-obesity drug market analysis report. Retrieved from GrandViewResearch.com.
[6] IQVIA Institute. (2023). Global use of medicines for obesity. Retrieved from IQVIA.com.
[7] Centers for Medicare & Medicaid Services. (2023). Expanded coverage for obesity treatments. Retrieved from CMS.gov.
[8] Vivus Inc. (2023). Annual financial report and market insights. Retrieved from Vivus.com.
[9] Evaluate Pharma. (2024). World preview 2024 outlook for obesity therapies. Retrieved from Evaluate.com.
[10] World Health Organization. (2023). Global obesity trends in Asia-Pacific. Retrieved from WHO.int.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.